DEF: KORU Medical Systems Sets Annual Shareholder Meeting

KORU Medical Systems, Inc. has issued its definitive proxy statement detailing the agenda for its 2026 Annual Meeting of Shareholders, including the election of directors and an amendment to its equity incentive plan.

Summary

• KORU Medical Systems, Inc. is holding its 2026 Annual Meeting of Shareholders on May 19, 2026, at its Mahwah, NJ office.
• Key agenda items include the election of directors, approval of an amendment to the 2024 Omnibus Equity Incentive Plan to increase the number of available shares, advisory approval of executive compensation, advisory vote on the frequency of future executive compensation votes, and ratification of the appointment of independent auditors.
• Shareholders of record as of March 16, 2026, are entitled to vote.
• The company is seeking shareholder approval to increase the number of shares available under its 2024 Omnibus Equity Incentive Plan from 2,300,000 to 4,600,000.
• The Board of Directors recommends voting 'FOR' the election of all director nominees, the plan amendment, the advisory approval of executive compensation, and the ratification of the independent auditors.
• The Board recommends voting for 'ONE YEAR' for the frequency of future advisory votes on executive compensation.
• Cherry Bekaert LLP has been selected as the independent registered public accounting firm for fiscal year 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard proxy statement for an annual meeting with routine proposals. While the equity plan amendment could lead to dilution, it is a common practice for growth companies.

Positives

• The company is actively engaging shareholders through its annual meeting process.
• The Board of Directors is composed of individuals with extensive experience in healthcare, medical devices, and finance.
• The company has a robust corporate governance framework, including independent committees and stock ownership guidelines for directors and executives.
• The proposed amendment to the equity incentive plan aims to attract and retain key personnel, aligning their interests with shareholders.
• The company maintains a Code of Ethics and has established procedures for risk oversight.
• KORU Medical Systems emphasizes product safety, quality, and compliance with global regulations.

Negatives

• The company is seeking to double the number of shares available under its equity incentive plan, which could lead to dilution for existing shareholders.
• There are instances of late Section 16(a) filings by certain directors and executive officers, indicating potential minor compliance oversights.
• The company has experienced net losses in recent fiscal years (2023 and 2025), as indicated by the pay-versus-performance data.

Risks

• Potential dilution of existing shareholders' equity due to the proposed increase in shares available under the 2024 Omnibus Equity Incentive Plan.
• The company's financial performance, as indicated by net losses in recent years, could pose a risk to future growth and shareholder value.
• The company's reliance on equity compensation to attract and retain talent could be impacted if market conditions or the plan's attractiveness change.

Future Outlook

The company is seeking shareholder approval to increase the number of shares available under its 2024 Omnibus Equity Incentive Plan, which is intended to help attract and retain key personnel and align their interests with shareholders. The company also anticipates holding its 2027 Annual Meeting of Shareholders, with deadlines for proposal submissions noted.

Management Comments

• "YOUR VOTE IS IMPORTANT."
• "We believe that the number of shares of common stock subject to the 2024 Equity Plan remaining available is insufficient to achieve the purposes of the 2024 Equity Plan and increasing the number of shares of common stock available under the 2024 Equity Plan will allow flexibility in granting awards to attract and retain key personnel by staying competitive with the labor market and further align the interests of our employees and shareholders while preserving our cash."
• "The Board believes that providing competitive compensation is necessary to attract and retain qualified non-employee directors."
• "Our goal is to provide an executive compensation program that best serves the long-term interests of our shareholders."
• "We are passionate about the culture we have created of openness, trust and mutual respect in our work environment."

Industry Context

StockSavvy.ai notes that KORU Medical Systems' proxy statement reflects common practices in the medical device industry, particularly regarding equity incentives for talent retention and board compensation structures. The proposed increase in equity awards is a typical strategy for growth-oriented companies in this sector to remain competitive in attracting and retaining skilled professionals.

Comparison to Industry Standards

• The proposed increase in the equity incentive plan shares from 2,300,000 to 4,600,000 represents a significant increase, which is not uncommon for companies seeking to fuel growth and retain talent in the competitive medtech sector.
• The compensation structure for non-employee directors, with a mix of cash retainers and stock awards (over half in stock), aligns with industry trends aimed at aligning director interests with shareholders.
• The company's focus on product safety, quality, and compliance with global regulations (ISO 13485, EU MDR, etc.) is a standard requirement for medical device manufacturers operating internationally.

Management Changes

Corporate Governance

Related Party Transactions

• No related party transactions exceeding $120,000 or 1% of average total assets for fiscal years 2024 and 2025 were disclosed.

Stakeholder Impact

• Shareholders: Potential equity dilution from the proposed increase in the equity incentive plan shares; advisory votes on executive compensation and director elections directly impact their governance rights.
• Employees: The equity incentive plan amendment aims to provide incentives for employees, potentially impacting retention and motivation.
• Directors: Compensation structure and stock ownership guidelines are detailed, aligning their interests with shareholders.
• Management: Executive compensation is detailed, with advisory votes on their pay and performance metrics.

Next Steps

• Shareholders will vote on the proposed matters at the 2026 Annual Meeting of Shareholders.
• The Board of Directors will consider shareholder feedback on executive compensation and its frequency.
• If approved, the amendment to the 2024 Omnibus Equity Incentive Plan will increase the number of authorized shares.
• Cherry Bekaert LLP will continue as the independent registered public accounting firm for fiscal year 2026, subject to shareholder ratification.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual shareholder meeting and does not contain new material financial information or strategic shifts that would warrant a buy or sell recommendation. The proposals are standard for corporate governance and compensation practices. Investors should hold their position while monitoring the company's operational and financial performance.

Keywords

KORU Medical Systems, Proxy Statement, Annual Meeting, Shareholder Meeting, Election of Directors, Equity Incentive Plan, Executive Compensation, Independent Auditors, Corporate Governance, SEC Filing, Schedule 14A